AC Immune (NASDAQ:ACIU) Now Covered by HC Wainwright

Stock analysts at HC Wainwright began coverage on shares of AC Immune (NASDAQ:ACIU) in a report issued on Thursday, Zacks reports. The firm set a “strong-buy” rating on the stock. HC Wainwright also issued estimates for AC Immune’s Q1 2027 earnings at $0.06 EPS, Q2 2027 earnings at $0.06 EPS, Q3 2027 earnings at $0.14 EPS and Q4 2027 earnings at $0.17 EPS.

Other research analysts have also recently issued research reports about the company. Zacks Research cut AC Immune from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 28th. Weiss Ratings raised shares of AC Immune from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. Finally, BTIG Research reiterated a “buy” rating and set a $8.00 price objective on shares of AC Immune in a research note on Wednesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, AC Immune currently has an average rating of “Moderate Buy” and a consensus target price of $7.50.

AC Immune Trading Down 7.9%

Shares of ACIU stock opened at $2.11 on Thursday. AC Immune has a 1 year low of $2.02 and a 1 year high of $3.90. The stock has a 50 day simple moving average of $2.55 and a 200 day simple moving average of $2.70.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $3.88 million for the quarter, compared to analyst estimates of $1.62 million. AC Immune had a negative return on equity of 97.79% and a negative net margin of 181.38%. On average, equities research analysts expect that AC Immune will post -0.60 earnings per share for the current year.

Hedge Funds Weigh In On AC Immune

Several hedge funds and other institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP lifted its position in shares of AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after buying an additional 176,701 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in AC Immune by 8.0% in the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after acquiring an additional 30,035 shares during the last quarter. Finally, AXQ Capital LP bought a new position in AC Immune in the second quarter valued at about $25,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.